Live
- Hate-hate relationship new trend in Indian politics
- Gadwal collector briefs on details of voters
- Jupally Krishna Rao takes part in Alampur rallu
- Bharath Prasad files 3rd Nomination
- Baisakh Month: A Time of Auspicious Beginnings and Sacred Festivals
- Oust BJD govt for overall development, says Shah
- Unveiling the Hidden Gems: Surprising Health Benefits of Garlic Peels
- Overcoming Sleep Struggles: A Comprehensive Guide to a Restful Night
- RTC bus hit the auto
- MLA Kuchukula Rajesh Reddy participated in the Birappa festival
Experimental Ebola vaccine safe, bolsters immunity
An experimental vaccine to prevent Ebola virus disease has been found to be well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial, researchers report.
Washington: An experimental vaccine to prevent Ebola virus disease has been found to be well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial, researchers report.
- Trials were conducted at the US National Institutes of Health's clinical centre
- Ebola vaccine contains segments of virus genetic material from two virus species
The trials were conducted at US National Institutes of Health's clinical centre in Bethesda, Maryland. The candidate vaccine is co-developed by the NIH's National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline (GSK).
“Based on these positive results from the first human trial of this candidate vaccine, we are continuing our accelerated plan for larger trials to determine if the vaccine is efficacious in preventing Ebola infection,” said NIAID director Anthony S. Fauci. The Ebola vaccine contains segments of Ebola virus genetic material from two virus species - Sudan and Zaire.
The Ebola virus genetic material is delivered by a carrier virus derived from chimpanzees that causes a common cold in chimpanzees but causes no illness in humans. The candidate vaccine does not contain Ebola virus and cannot cause Ebola virus disease. The trial enrolled volunteers between ages 18 and 50. Ten volunteers received vaccine at a lower dose and 10 received the same vaccine at a higher dose.
